IPSEN, OOO
- Country
- 🇷🇺Russia
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK
- Conditions
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 108
- Registration Number
- NCT03696407
- Locations
- 🇬🇧
Royal Sussex County Hospital, Brighton, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)
- Conditions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 607
- Registration Number
- NCT03689673
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, China
🇨🇳Union Hospital Affiliated to Tongji Medical College, Wuhan, China
🇨🇳China-Japan Union Hospital of Jilin University, Changchun, China
Dysport in Post-Surgical Neuralgia
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 16
- Registration Number
- NCT03663101
- Locations
- 🇬🇧
St Pancras Clinical Research, London, United Kingdom
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
- Conditions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 210
- Registration Number
- NCT03647878
- Locations
- 🇦🇹
Landeskrankenhaus Hochsteiermark, Leoben, Austria
🇦🇹Ordensklinikum Linz GmbH, Linz, Austria
🇦🇹Kepler Universitätsklinikum GmbH, Linz, Austria
Dysport in Vulvodynia Phase II Study
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 60
- Registration Number
- NCT03598777
- Locations
- 🇺🇸
Seattle Women's: Health, Research, Gynecology®, Seattle, Washington, United States
🇺🇸The Center for Vulvovaginal Disorders, New York, New York, United States
🇺🇸New Age Medical Research Corporation, Miami, Florida, United States
Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis
- Conditions
- First Posted Date
- 2018-07-13
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 465
- Registration Number
- NCT03586063
- Locations
- 🇷🇺
Scientific center of Family Health Problems and Human reproduction of Siberian branch of RAMS, Irkutsk, Russian Federation
🇷🇺SEI Irkutsk State medical refresher institute, Irkutsk, Russian Federation
🇷🇺City hospital #2, Krasnodar multi-field medical diagnostic association, endoscopic gynecology center, Krasnodar, Russian Federation
Dysport in Hallux Abducto Valgus (HAV) Phase IIa
- Conditions
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 186
- Registration Number
- NCT03569098
- Locations
- 🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸Foot and Ankle Clinic, Los Angeles, California, United States
🇺🇸Ankle and Foot Care Centers, Youngstown, Ohio, United States
Efficacy, Safety and Tolerability of a New Bowel Cleansing Preparation (BLI800) in Adult Subjects Undergoing Colonoscopy
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 297
- Registration Number
- NCT03562884
- Locations
- 🇨🇳
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
🇨🇳Zhong Shan Hospital, Shanghai, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel
- Conditions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 115
- Registration Number
- NCT03562091
- Locations
- 🇫🇷
Ipsen Central Contact, Paris, France
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
- First Posted Date
- 2018-05-15
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 14
- Registration Number
- NCT03525392
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇨🇭CHU Vaudois, Lausanne, Switzerland
🇨🇭Universitäts Spital Zürich, Zürich, Switzerland